{"id":"osimertinib-mesylate-tablets","safety":{"commonSideEffects":[{"rate":"55","effect":"Diarrhea"},{"rate":"40","effect":"Rash"},{"rate":"25","effect":"Dry skin"},{"rate":"20","effect":"Nausea"},{"rate":"15","effect":"Stomatitis"},{"rate":"5","effect":"QT prolongation"},{"rate":"1-2","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL3545063","moleculeType":"Small molecule","molecularWeight":"595.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Osimertinib binds irreversibly to mutant EGFR (epidermal growth factor receptor) while showing reduced activity against wild-type EGFR, allowing it to overcome resistance that develops when first- and second-generation EGFR inhibitors select for the T790M mutation. This selective targeting of mutant EGFR leads to sustained inhibition of downstream signaling pathways that drive cancer cell proliferation and survival.","oneSentence":"Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor that selectively targets EGFR mutations, including the T790M resistance mutation, in non-small cell lung cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:51.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer with EGFR T790M mutation (acquired resistance)"},{"name":"Non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line treatment)"}]},"trialDetails":[{"nctId":"NCT06970639","phase":"PHASE3","title":"A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-09-26","conditions":"NSCLC Patients With Brain Metastasis","enrollment":380},{"nctId":"NCT07322783","phase":"PHASE2","title":"Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification","status":"RECRUITING","sponsor":"Qingdao Central Hospital","startDate":"2025-01-01","conditions":"EGFR Positive Non-small Cell Lung Cancer, MET Amplification","enrollment":60},{"nctId":"NCT07256509","phase":"PHASE2","title":"A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-30","conditions":"Non-Small Cell Lung Cancer","enrollment":120},{"nctId":"NCT04001777","phase":"PHASE1","title":"A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascentage Pharma Group Inc.","startDate":"2019-07-04","conditions":"EGFR Positive Non-small Cell Lung Cancer","enrollment":80},{"nctId":"NCT05020769","phase":"PHASE2, PHASE3","title":"SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2022-01-06","conditions":"Non-small Cell Lung Cancer","enrollment":14},{"nctId":"NCT05880706","phase":"PHASE2","title":"A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2023-07-19","conditions":"Non-small Cell Lung Cancer","enrollment":198},{"nctId":"NCT06498986","phase":"PHASE2","title":"A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-07-31","conditions":"Non-small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06895928","phase":"PHASE2","title":"A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2025-03-28","conditions":"Advanced Solid Tumors","enrollment":400},{"nctId":"NCT06908772","phase":"PHASE2, PHASE3","title":"Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2025-04-01","conditions":"Recurrent or Metastatic NSCLC Patients With Classical EGFR Mutations Accompanied by MET Amplification or Overexpression","enrollment":390},{"nctId":"NCT06306456","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC","status":"RECRUITING","sponsor":"Suzhou Genhouse Bio Co., Ltd.","startDate":"2024-03-05","conditions":"Non-Small Cell Lung Cancer With EGFR Mutation","enrollment":94},{"nctId":"NCT05489731","phase":"PHASE1","title":"VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.","startDate":"2022-09-21","conditions":"Advanced Non-small Cell Lung Cancer","enrollment":72},{"nctId":"NCT04438902","phase":"PHASE2","title":"Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment","status":"TERMINATED","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2020-12-12","conditions":"Non Small Cell Lung Cancer","enrollment":3},{"nctId":"NCT04798638","phase":"PHASE1","title":"A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers","status":"COMPLETED","sponsor":"TYK Medicines, Inc","startDate":"2021-04-30","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT05284994","phase":"PHASE1, PHASE2","title":"TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2022-03-11","conditions":"Nonsmall-cell Lung Cancer","enrollment":160},{"nctId":"NCT05132777","phase":"PHASE2","title":"Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2021-11-20","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations","enrollment":155},{"nctId":"NCT03460275","phase":"PHASE2","title":"Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-02-26","conditions":"Non-small Cell Lung Cancer","enrollment":100},{"nctId":"NCT03050411","phase":"PHASE1","title":"Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2016-05","conditions":"Nonsmall Cell Lung Cancer","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AZD9291","TAGRISSO"],"phase":"phase_3","status":"active","brandName":"Osimertinib Mesylate Tablets","genericName":"Osimertinib Mesylate Tablets","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Osimertinib is a third-generation, irreversible tyrosine kinase inhibitor that selectively targets EGFR mutations, including the T790M resistance mutation, in non-small cell lung cancer. Used for Non-small cell lung cancer with EGFR T790M mutation (acquired resistance), Non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations (first-line treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}